ASK AN EXPERT

nLiven PR™


Notice: Trying to access array offset on value of type bool in /nas/content/live/sextonbio/wp-content/themes/sexton2021/single-products.php on line 31

Notice: Trying to access array offset on value of type null in /nas/content/live/sextonbio/wp-content/themes/sexton2021/single-products.php on line 31

Notice: Trying to access array offset on value of type bool in /nas/content/live/sextonbio/wp-content/themes/sexton2021/single-products.php on line 57

Notice: Trying to access array offset on value of type null in /nas/content/live/sextonbio/wp-content/themes/sexton2021/single-products.php on line 57
Price: $578
ADD TO CART REQUEST MORE INFO

GMP-ready pathogen reduced human platelet lysate.

As global regulatory expectations evolve, Sexton Biotechnologies is there to meet the challenge. With a validated pathogen reduction technology, nLiven PR established the gold standard for performance and quality of irradiated pooled human platelet lysate.

SPECIFICATIONS
DETAILS
  • Validated pathogen reduction technology using E-Beam irradiation
  • Available in 100, 500 ml
  • Large donor pool lot sizes
  • Manufactured from outdated FDA/AABB approved apheresis platelet units
  • FDA master file, PMDA Certificate of Suitability
  • Used for manufacturing in US, EU, and other clinical trials globally
  • Manufactured under a certified ISO 9001:2015 Quality Management System
  • Example CoA and IFU
  • Culture supplement to replace FBS or AB Serum
  • BioDefined composition reduces lot-to-lot variability
  • Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more.
  • Promotes improved in vitro and In vivo cell quality in CAR-T applications
  • Typically used at 2%-10% concentrations.
  • Used in 2D and 3D expansion systems
  • Additional pathogen reduction applied per EU pharmacopeia

RESOURCES